ArticlePloS one2009
Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.Frontiers in neurology · 2020Pooled it
- Role of Oxidative Stress in Human Neurodegenerative Pathologies: Lessons from theCurrent topics in medicinal chemistry · 2026Review
- Reduction of APOE accounts for neurobehavioral deficits in fetal alcohol spectrum disorders.Molecular psychiatry · 2024Article
- Towards early detection of neurodegenerative diseases: A gut feeling.Frontiers in cell and developmental biology · 2023Review
- Apolipoprotein E and Alzheimer's disease.Acta pharmaceutica Sinica. B · 2022Review
- COG133 Attenuates the Early Brain Injury Induced by Blood-Brain Barrier Disruption in Experimental Subarachnoid Hemorrhage.Journal of healthcare engineering · 2022Article
- Empowering Melatonin Therapeutics withDiseases (Basel, Switzerland) · 2021Review
- Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury.Experimental neurology · 2018Article
- HumanNeural plasticity · 2017Article
- A Novel Genetic Screen Identifies Modifiers of Age-Dependent Amyloid β Toxicity in theFrontiers in aging neuroscience · 2017Article
- Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans.Frontiers in immunology · 2017Review
- Role ofFrontiers in molecular neuroscience · 2016Review
- Bidirectional Regulation of Amyloid Precursor Protein-Induced Memory Defects by Nebula/DSCR1: A Protein Upregulated in Alzheimer's Disease and Down Syndrome.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Article
- Review
- Drosophila models of proteinopathies: the little fly that could.Current pharmaceutical design · 2012Review
- Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells.Disease models & mechanisms · 2011Article
- Characterization of a Drosophila Alzheimer's disease model: pharmacological rescue of cognitive defects.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations of the amyloid precursor protein gene (APP) are found in familial forms of Alzheimer's disease (AD) and some lead to the elevated production of amyloid-beta-protein (Abeta). While Abeta has been implicated in the causation of AD, the exact role played by Abeta and its APP precursor are still unclear. PRINCIPAL
findingsIn our study, Drosophila melanogaster transgenics were established as a model to analyze AD-like pathology caused by APP overexpression. We demonstrated that age related changes in the levels and pattern of synaptic proteins accompanied progressive neurodegeneration and impairment of cognitive functions in APP transgenic flies, but that these changes may be independent from the generation of Abeta. Using novel peptide mimetics of Apolipoprotein-E, COG112 or COG133 proved to be neuroprotective and significantly improved the learning and memory of APP transgenic flies.
conclusionsThe development of neurodegeneration and cognitive deficits was corrected by injections of COG112 or COG133, novel mimetics of apolipoprotein-E (apoE) with neuroprotective activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.